Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers
Elizabeth F. Krakow(Fred Hutch Cancer Center), Anthony D. Sung(Cornell University), Kai‐Xun Hu(Academy of Military Medical Sciences), Hui‐Sheng Ai(Academy of Military Medical Sciences), Brian C. Shaffer(Memorial Sloan Kettering Cancer Center), Jean‐Sébastien Delisle(Hôpital Maisonneuve-Rosemont)
Cited by 16
Related Papers
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2020|739
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity
|Blood Advances|2018|206
Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease
|Biology of Blood and Marrow Transplantation|2017|87
Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients
|Biology of Blood and Marrow Transplantation|2018|49